The Gurgaon-headquartered drug maker, set to be acquired by another leading domestic company, Sun Pharmaceutical Industries, reported a consolidated net loss of Rs 186 crore for the quarter ended June.
Industry is gathering scientific data to approach the regulator, DCGI, for a review of the suspension order.
The FDA has stepped up its efforts to ensure drug safety in recent months.
In 2014, Sun Pharma agreed to buy Ranbaxy -- which was then controlled by Daiichi.
Hero MotoCorp's promoter Pawan Munjal emerged as the highest paid director.
The BSE Mid-cap index gained 1.1% while the Small-cap index surged 1.3%, outperforming the benchmark indices
Amneal Pharmaceuticals is set to pip Sun Pharma as the fifth largest generics maker in the US, reports Sohini Das.
Sun Pharma to retain these in most markets; US could be the exception, where the Ranbaxy name has taken a hit.
On January 31, the US Federal Trade Commission cleared the merger.
Ranbaxy Laboratories on Wednesday reported widening of its consolidated net loss to Rs 1,029.72 crore (Rs 10.29 billion) for the third quarter ended December 31, 2014
Launches cloud-based version of solution to target mid-size clients in life sciences.
It goes without saying that the best performers are in the private sector, says TN Ninan.
Analysts say those taking exposure through stocks could look at firms focused on domestic business
Currently, only three have completed more than six months of operation in the space - Fino Payments Bank, Airtel Payments Bank and Paytm
A source said the competition watchdog would by next month suggest 'structural remedies' that included selling key drug segments as conditions for clearing the country's largest pharmaceutical industry merger.
The Nifty50 slipped 33 points to close the session at 8,509 after hitting an intra-day high of 8,587.
The turmoil on the Street and a continued fall of the rupee may affect growth stocks, pushing equity investors back to the relative safety of defensive counters, or forcing them to flee markets, or both.
On October 2, a legislature committee wrote letters to the 14 companies, initiating an investigation and seeking details about recent price increases in several generic products available in the American market.
The US Food and Drug Administration (FDA) says it does not follow an India agenda.
The year saw 30 QIP deals raising over $5 billion and 35 IPOs.
Top losers are Sun Pharma, Bajaj Auto, L&T, ITC, Hero Moto.
Some Indian generic drugmakers are, however, uncertain about the pace of approvals in the near future.
In 2013, Daiichi had launched the arbitration proceedings in Singapore.
In August, RBI allowed 11 business houses to start a payments bank.
Of the 23 Indian billionaires mentioned in the Bloomberg Billionaires Index, only one saw a reduction in net worth, with the companies owned by most of them outperforming the Nifty 50 index by a big margin.
Combined net profit estimated to grow 14.6% year-on-year, against a 5.7% decline in the Dec 2015 quarter
Slapped with Rs 242-crore fine by US authorities for rule violations at Toansa unit, say sources; 2nd such hefty rap in the recent past from US regulators for bending rules.
US will remain a growth driver, with launches & existing portfolios set to result in 15% growth for FY15.
Additional levy to eat into Rs 6,000-crore income of top promoters
The Ranbaxy experience has made multinational corporations more cautious about Indian acquisitions in general
There are just 1,500 drug inspectors responsible for more than 10,000 factories in India
Besides opposing the suspension of three medicines, the sector has also questioned the process adopted by the government.
This analysis is based on the quarterly earnings for 724 companies.
According to industry estimates, the sector's revenue would increase eight-10 per cent in 2013-14, against 12 per cent in 2012-13.
Samvat 2070 was a great year for top Indian conglomerates in the stock markets.
Sun maintained it would retain the best of both organisations to build a global pharma company.
US country head, key departmental heads leave; more likely to follow.
Top ten billionaires in India.
Ajit Mishra, vice president, Research, Religare Broking, answers readers' queries on stocks they own or want to buy.
Sun-Ranbaxy are keen to complete the merger process.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances